CytomX Therapeutics to Announce Second Quarter 2016 Financial Results and Provide Mid-Year Update
2016年7月28日 - 5:30AM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, will announce financial results for the second
quarter ended June 30, 2016, and provide a mid-year update on
August 3, 2016, after the NASDAQ market close.
The company will not be conducting a conference
call in conjunction with this earnings release.
About CytomX TherapeuticsCytomX is
an oncology-focused biopharmaceutical company pioneering a novel
class of investigational antibody therapeutics based on its Probody
technology platform. The company uses the platform to create
development-stage proprietary cancer immunotherapies against
clinically-validated targets, as well as to develop first-in-class
investigational cancer therapeutics against novel targets. CytomX
believes that its Probody platform has the potential to improve the
combined efficacy and safety profile of monoclonal antibody
modalities, including cancer immunotherapies, antibody drug
conjugates and T-cell-recruiting bispecific antibodies. Probody
therapeutics are designed to take advantage of unique conditions in
the tumor microenvironment to enhance the tumor-targeting features
of an antibody and reduce drug activity in healthy tissues.
Investigational Probody therapeutics are being developed that
address clinically-validated cancer targets in immuno-oncology,
such as PD-L1, against which clinical candidate CX-072 is directed,
as well as novel targets, such as CD-166, that are difficult to
drug without causing damage to healthy tissues, or toxicities. In
addition to its proprietary programs, CytomX is collaborating with
strategic partners including AbbVie Inc., Bristol-Myers Squibb
Company, Pfizer Inc., MD Anderson Cancer Center, and ImmunoGen,
Inc. For more information, visit www.cytomx.com.
Forward-Looking StatementsThis
press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements. Accordingly, you should not rely on any
of these forward-looking statements. Our Probody platform is in
preclinical development, and the process by which a preclinical
technology could potentially lead to an approved product is long
and subject to significant risks and uncertainties. Applicable
risks and uncertainties include those relating to our preclinical
research and development and other risks identified under the
heading "Risk Factors" included in our filings with the SEC. The
forward-looking statements contained in this press release are
based on information currently available to CytomX and speak only
as of the date on which they are made. CytomX does not undertake
and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Corporate Communications Contact:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contact:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024